408 related articles for article (PubMed ID: 29211044)
1. Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinson's and Alzheimer's Diseases.
Boyko AA; Troyanova NI; Kovalenko EI; Sapozhnikov AM
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211044
[TBL] [Abstract][Full Text] [Related]
2. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
Clark LF; Kodadek T
ACS Chem Neurosci; 2016 May; 7(5):520-7. PubMed ID: 27046268
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's Disease is Accompanied by Intertwined Alterations in Iron Metabolism and Activated Immune-inflammatory and Oxidative Stress Pathways.
de Farias CC; Maes M; Bonifacio KL; Matsumoto AK; Bortolasci CC; Nogueira AS; Brinholi FF; Morimoto HK; de Melo LB; Moreira EG; Barbosa DS
CNS Neurol Disord Drug Targets; 2017; 16(4):484-491. PubMed ID: 28240188
[TBL] [Abstract][Full Text] [Related]
4. Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients.
Montarolo F; Perga S; Martire S; Navone DN; Marchet A; Leotta D; Bertolotto A
Neurotox Res; 2016 Oct; 30(3):338-44. PubMed ID: 27159982
[TBL] [Abstract][Full Text] [Related]
5. The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases.
Sommer A; Winner B; Prots I
Mol Neurodegener; 2017 Oct; 12(1):78. PubMed ID: 29078813
[TBL] [Abstract][Full Text] [Related]
6. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.
Dursun E; Gezen-Ak D; Hanağası H; Bilgiç B; Lohmann E; Ertan S; Atasoy İL; Alaylıoğlu M; Araz ÖS; Önal B; Gündüz A; Apaydın H; Kızıltan G; Ulutin T; Gürvit H; Yılmazer S
J Neuroimmunol; 2015 Jun; 283():50-7. PubMed ID: 26004156
[TBL] [Abstract][Full Text] [Related]
7. The role of Th17 cells in auto-inflammatory neurological disorders.
Tahmasebinia F; Pourgholaminejad A
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):408-416. PubMed ID: 28760387
[TBL] [Abstract][Full Text] [Related]
8. Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.
Reale M; Greig NH; Kamal MA
Mini Rev Med Chem; 2009 Sep; 9(10):1229-41. PubMed ID: 19817713
[TBL] [Abstract][Full Text] [Related]
9. An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases.
Batistela MS; Josviak ND; Sulzbach CD; de Souza RL
Int J Neurosci; 2017 Jun; 127(6):547-558. PubMed ID: 27381850
[TBL] [Abstract][Full Text] [Related]
10. Serum heme oxygenase-1 levels are increased in Parkinson's disease but not in Alzheimer's disease.
Mateo I; Infante J; Sánchez-Juan P; García-Gorostiaga I; Rodríguez-Rodríguez E; Vázquez-Higuera JL; Berciano J; Combarros O
Acta Neurol Scand; 2010 Feb; 121(2):136-8. PubMed ID: 19785642
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines.
Alam Q; Alam MZ; Mushtaq G; Damanhouri GA; Rasool M; Kamal MA; Haque A
Curr Pharm Des; 2016; 22(5):541-8. PubMed ID: 26601965
[TBL] [Abstract][Full Text] [Related]
12. Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review.
Singh K; Cheung BM; Xu A
Biomark Med; 2021 Dec; 15(17):1693-1708. PubMed ID: 34743546
[No Abstract] [Full Text] [Related]
13. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Kim S; Seo JH; Suh YH
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
[TBL] [Abstract][Full Text] [Related]
14. Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson's disease?
Roy A; Mondal B; Banerjee R; Choudhury S; Chatterjee K; Dey S; Kumar H
J Neuroimmunol; 2021 May; 354():577545. PubMed ID: 33756415
[TBL] [Abstract][Full Text] [Related]
15. Unfolded p53 as a Marker of Oxidative Stress in Mild Cognitive Impairment, Alzheimer's and Parkinson's Disease.
García S; Amor-Gutiérrez O; Palomares-Albarrán M; Toyos-Rodríguez C; Cuetos F; Martínez C; Costa-García A; Fernández-Sánchez MT; de la Escosura-Muñiz A; Novelli A
Curr Alzheimer Res; 2021; 18(9):695-700. PubMed ID: 34789127
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte thiolmethyltransferase: another failed marker for Alzheimer's and Parkinson's diseases.
Hurwitz A; Hubble JP; Glatt SL; Koller WC; Pollack J
Neurology; 1995 Oct; 45(10):1903-6. PubMed ID: 7477990
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors.
Araujo DM; Lapchak PA
Neuroscience; 1994 Aug; 61(4):745-54. PubMed ID: 7838374
[TBL] [Abstract][Full Text] [Related]
18. Peripheral expression of MAPK pathways in Alzheimer's and Parkinson's diseases.
Wang S; Zhang C; Sheng X; Zhang X; Wang B; Zhang G
J Clin Neurosci; 2014 May; 21(5):810-4. PubMed ID: 24405770
[TBL] [Abstract][Full Text] [Related]
19. Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease.
Kuiper MA; van Kamp GJ; Bergmans PL; Scheltens P; Wolters EC
J Neural Transm Park Dis Dement Sect; 1993; 6(2):145-9. PubMed ID: 8117411
[TBL] [Abstract][Full Text] [Related]
20. miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.
Mushtaq G; Greig NH; Anwar F; Zamzami MA; Choudhry H; Shaik MM; Tamargo IA; Kamal MA
Med Chem; 2016; 12(3):217-25. PubMed ID: 26527155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
